DIADIA0.01%
SPYSPY0.09%
QQQQQQ0.35%
Trending
Top trending tickerSPCXSPCX5.90%
NOWNOW6.18%
GOOGLGOOGL0.54%
GOOGGOOG0.36%
PATHPATH12.21%
CAPRCAPR4.25%
PLTRPLTR6.55%
TSLATSLA1.02%
TTDTTD4.22%
PSKYPSKY3.40%
Top trending tickerSPCXSPCX5.90%
NOWNOW6.18%
GOOGLGOOGL0.54%
GOOGGOOG0.36%
PATHPATH12.21%
CAPRCAPR4.25%
PLTRPLTR6.55%
TSLATSLA1.02%
TTDTTD4.22%
PSKYPSKY3.40%

Feed

News

Sentiment

Earnings

Fundamentals

Info

homeSymbolVERAnews
Exchange: NASDAQ·Updated 03:40 PM EDT
VERA logo

VERAVera Therapeutics Inc - Ordinary Shares - Class A

$36.48
$0.69
(1.86%)
Today
EarningsAug 4
Mkt Cap$2.67B
Vol488,990.00
News
all
press releases
VERA Stock Surges After Drug To Treat Rare Kidney Disease Gets FDA Approval – Retail Sees The Move As Catalyst For Vera Therapeutics
Vera Therapeutics' Trutakna received an early, fast-tracked approval from the FDA to reduce proteinuria in adults with primary IgA Nephropathy whose health is at risk of deterioration.
Stocktwits
More News
Why Is Vera Therapeutics Stock Gaining Tuesday?
Vera Therapeutics (VERA) stock jumps 9% following FDA accelerated approval for its kidney disease drug Trutakna. Full analysis here.read more...
Benzinga
VERA Stock Rallies Ahead Of High-Stakes FDA Decision On Lead Kidney Disease Drug – Retail Sees 35% Potential Upside
The U.S. Food and Drug Administration is set to announce its decision on Atacicept later on Monday, paving the way for the potential commercialization of the drug in the U.S.
Stocktwits
Vera Therapeutics Moves Closer To Full Approval For Kidney Disease Drug After FDA Alignment
The biotech moves a step closer to full approval in IgAN as regulators agree to an accelerated timeline for key kidney function data review.
Stocktwits
Pictet Asset Management Holding SA Cuts Stake in Vera Therapeutics, Inc. $VERA
Pictet Asset Management Holding SA cut its stake in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 3.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,392,421 shares of the company's stock after sellin...
MarketBeat
Vera Therapeutics (VERA) to Release Earnings on Tuesday
Vera Therapeutics (NASDAQ:VERA) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 5. (View Earnings Report at...
MarketBeat
Vera Therapeutics (NASDAQ:VERA) CEO Marshall Fordyce Sells 22,951 Shares
Vera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) CEO Marshall Fordyce sold 22,951 shares of the company's stock in a transaction on Tuesday, April 14th. The shares were sold at an average price of $44.05, for a total value of $1,010,991.55. Following the completion of the transaction, the...
MarketBeat
Vera Therapeutics, Inc. (NASDAQ:VERA) Given Average Recommendation of "Moderate Buy" by Analysts
Vera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) has earned a consensus rating of "Moderate Buy" from the twelve analysts that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and t...
MarketBeat
Vera Therapeutics (NASDAQ:VERA) CEO Sells $1,010,991.55 in Stock
Vera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) CEO Marshall Fordyce sold 22,951 shares of the company's stock in a transaction on Tuesday, April 14th. The shares were sold at an average price of $44.05, for a total value of $1,010,991.55. Following the transaction, the chief executive...
MarketBeat
AMI Asset Management Corp Makes New $1.44 Million Investment in Vera Therapeutics, Inc. $VERA
AMI Asset Management Corp bought a new position in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange...
MarketBeat
<
1
2
...
>

Advertisement|Remove ads.

Advertisement|Remove ads.